Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study

• Published in: Experimental and therapeutic medicine Vol. 3; no. 1; pp. 60 - 65
• Main Authors: KAKU, HIROI, KUMAGAI, SEISUKE, ONOUE, HIROKI, TAKADA, ANNA, SHOJI, TADAHIRO, MIURA, FUMIHARU, YOSHIZAKI, AKIRA, SATO, SHINYA, KIGAWA, JUNZO, ARAI, TSUTOMU, TSUNODA, SHINPEI, TOMINAGA, EIICHIRO, AOKI, DAISUKE, SUGIYAMA, TORU
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.01.2012
• Subjects: Goshajinkigan; gynecological cancer; Japanese herbal medicine; kampo drugs; neurotoxicity; paclitaxel; peripheral neuropathy
• DOI: 10.3892/etm.2011.375
• ISSN: 1792-0981

Paclitaxel/carboplatin chemotherapy for cancer (TC therapy) exhibits neurotoxicity and causes peripheral neuropathy at a high frequency, which is difficult to cope with. In this study, we investigated the efficacy of Goshajinkigan, a traditional Japanese herbal medicine, for TC therapy-induced peripheral neuropathy. The subjects included in our study were patients with ovarian or endometrial cancer who underwent TC therapy and developed peripheral neuropathy. The patients were randomly divided into Group A, comprising of 14 patients (vitamin B12 treatment), and Group B, comprising of 15 patients (vitamin B12 + Goshajinkigan treatment). The observation period was 6 weeks following treatment initiation, and the evaluation items were as follows: i) the current perception threshold (CPT value) of the peripheral nerve, ii) visual analogue scale for numbness, iii) National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade of neurotoxicity, and iv) a questionnaire on the subjective symptoms of peripheral neuropathy (functional assessment of cancer therapy-taxane). These were compared between the groups and no significant differences were noted in any item. However, CTCAE grade 3 neurotoxicity developed in 2 patients (14.3%) after 6 weeks of administration in Group A, whereas no neurotoxicity was observed in Group B. When the change in the frequency of abnormal CPT ratio at 6 weeks of administration from that before treatment was compared between the groups, the frequency of abnormal value was significantly lower in Group B than in Group A (p<0.05). This suggests that Goshajinkigan inhibits the progression of peripheral neuropathy.